表紙
市場調査レポート

脊髄性筋萎縮症(SMA):世界の治験レビュー

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 309956
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
脊髄性筋萎縮症(SMA):世界の治験レビュー Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014
出版日: 2014年07月31日 ページ情報: 英文
概要

当レポートでは、脊髄性筋萎縮症(SMA)に関する臨床研究の最新動向について分析し、疾患治療法の概要や、治験における主要国、G7諸国およびE7(新興7カ国)における治験数および被験者採用の状況、フェーズ(相)段階別の進行状況、有望なスポンサー、各企業研究機関での研究の進行状況、有望な薬剤の比較といった情報をまとめてお届けします。

目次

イントロダクション

  • 脊髄性筋萎縮症(SMA)
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東およびアフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:中枢神経系の治験件数に対する脊髄性筋萎縮症(SMA)の治験件数比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国(新興7カ国)での治験件数:中枢神経系の治験件数に対する脊髄性筋萎縮症(SMA)の治験件数比率

E7諸国(新興7カ国)での治験件数:フェーズ(相)別

E7諸国(新興7カ国)での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ(相)別

進捗状況別の治験件数

エンドポイント達成状況別の治験件数

未達成の治験件数

一定期間に採用された被験者

スポンサーの種類別治験件数

有望なスポンサー

有望な薬剤

治験のプロファイル

  • 代表的な企業の治験概要
    • Isis Pharmaceuticals, Inc.
    • Trophos SA
    • Westat, Inc.
    • Repligen Corporation
    • PTC Therapeutics, Inc.
    • Natera, Inc.
    • Hill-Rom Holdings, Inc.
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd.
  • 代表的な研究機関・病院の治験の概要
    • University of Utah
    • National Institute of Neurological Disorders and Stroke
    • Columbia University
    • Assistance Publique - Hopitaux de Paris
    • Stanford University
    • All India Institute of Medical Sciences
    • 名古屋大学
    • JASMITT Clinical Trial Office
    • National Taiwan University Hospital
    • University Hospital Freiburg

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GlobalData

GlobalData's clinical trial report, "Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014" provides data on the Spinal Muscular Atrophy (SMA) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Muscular Atrophy (SMA). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Muscular Atrophy (SMA). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Spinal Muscular Atrophy (SMA)
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Spinal Muscular Atrophy (SMA)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Isis Pharmaceuticals, Inc.
      • Clinical Trial Overview of Isis Pharmaceuticals, Inc.
      • Trophos SA
      • Clinical Trial Overview of Trophos SA
      • Westat, Inc.
      • Clinical Trial Overview of Westat, Inc.
      • Repligen Corporation
      • Clinical Trial Overview of Repligen Corporation
      • PTC Therapeutics, Inc.
      • Clinical Trial Overview of PTC Therapeutics, Inc.
      • Natera, Inc.
      • Clinical Trial Overview of Natera, Inc.
      • Hill-Rom Holdings, Inc.
      • Clinical Trial Overview of Hill-Rom Holdings, Inc.
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
    • Clinical Trial Overview of Top Institutes / Government
      • University of Utah
      • Clinical Trial Overview of University of Utah
      • National Institute of Neurological Disorders and Stroke
      • Clinical Trial Overview of National Institute of Neurological Disorders and Stroke
      • Columbia University
      • Clinical Trial Overview of Columbia University
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
      • Stanford University
      • Clinical Trial Overview of Stanford University
      • All India Institute of Medical Sciences
      • Clinical Trial Overview of All India Institute of Medical Sciences
      • Nagoya University
      • Clinical Trial Overview of Nagoya University
      • JASMITT Clinical Trial Office
      • Clinical Trial Overview of JASMITT Clinical Trial Office
      • National Taiwan University Hospital
      • Clinical Trial Overview of National Taiwan University Hospital
      • University Hospital Freiburg
      • Clinical Trial Overview of University Hospital Freiburg
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Trophos SA, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Westat, Inc., 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Repligen Corporation, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Natera, Inc., 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hill-Rom Holdings, Inc., 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Utah, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagoya University, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by JASMITT Clinical Trial Office, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Freiburg, 2014*

List of Figures

  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top